Free Trial
$100 Off Ends Tonight! MarketBeat All Access Returns to $249
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Save $100 Now
Claim MarketBeat All Access Sale Promotion
NASDAQ:IMA

ImageneBio Q3 2024 Earnings Report

ImageneBio logo
$5.56 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$5.64 +0.08 (+1.35%)
As of 05/22/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

ImageneBio EPS Results

Actual EPS
-$2.28
Consensus EPS
-$3.24
Beat/Miss
Beat by +$0.96
One Year Ago EPS
N/A

ImageneBio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ImageneBio Announcement Details

Quarter
Q3 2024
Date
11/7/2024
Time
N/A
Conference Call Date
Thursday, November 7, 2024
Conference Call Time
8:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

ImageneBio's Q3 2024 Quarterly reportQuarterly report
(10-Q)

ImageneBio Earnings Headlines

ImageneBio (NASDAQ:IMA) Downgraded by Wall Street Zen to Strong Sell
May 17, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30782478
ImageneBio (IMA) price target decreased by 18.75% to 13.26
May 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/imagenebio-ima-price-target-decreased-by-1875-to-1326/ar-AA239i1S
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
May 25 at 1:00 AM  |  InvestorPlace (Ad)
ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290583/0/en/imagenebio-reports-first-quarter-2026-financial-results-and-provides-img-007-program-update.html
ImageneBio Inc.
April 13, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/ima/company-people
IMA stock surges 24%, breaks 50-DMA for first time since February – what's driving the rally?
April 13, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/ima-stock-surges-24-breaks-50-dma-for-first-time-since-february-whats-driving-the-rally/ar-AA20Ns5C
See More ImageneBio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ImageneBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImageneBio and other key companies, straight to your email.

About ImageneBio

ImageneBio (NASDAQ:IMA), a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

View ImageneBio Profile
Earnings Tools